Market Intelligence, Clinical Progress, and High-Purity Reagents for Treg-Targeted Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LRRC32 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRRC32 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View LRRC32 Products |
| Gene Delivery | LRRC32 Lentivirus Particles. Full-length ORF for stable Treg/Teff cell line construction. Suitable for internalization assays. | View LRRC32 Products |
| Benchmark Ab | Anti-LRRC32 (GARP) Reference Antibody. Recombinant positive control for blocking and binding assays. | View LRRC32 Products |
| Validator | LRRC32 siRNA Set. For knockdown verification and specificity controls. | View LRRC32 Products |
| TGFB1 (LAP Complex Partner) | Essential for functional binding assays and TGF-β release assays. | View TGFB1 Products |
| TGFBR2 (Signaling Receptor) | Downstream signaling validation and counter-screening. | View TGFBR2 Products |
| CTLA4 (Synergistic Immune Checkpoint) | Synergistic immune checkpoint on Regulatory T cells (Tregs). | View CTLA4 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (cyno/mouse) | Human/Mouse/Cyno LRRC32 ortholog proteins available with >95% purity; sequence verified by mass spec. |
| TGF-β Release Inhibition Assay (Mechanism validation) | LRRC32-TGF-β1 Complex Formation Kits; pH-stability verified proteins for integrin-independent binding studies. |
| Internalization Efficiency (ADC development) | Full-length LRRC32 Lentivirus for stable cell lines; preserves conformation for flow cytometry-based uptake assays. |
| Conformational Binding (TGF-beta complex) | HEK293 Expressed (Native Glycosylation) to ensure proper structural folding. |
| False Positives / Off-target binding | Validated siRNA included for specificity checks; sequence-verified negative controls. |
Live LRRC32 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRRC32 (GARP)-targeted therapeutics is intensifying, with major players shifting focus from traditional immune checkpoint inhibitors to modulating the tumor microenvironment (TME) via Treg suppression. LRRC32 tethers latent TGF-beta to the surface of Tregs, making it a critical node for immunosuppression. As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecific modalities linking GARP to TGF-beta or PD-1 to precisely block TGF-beta activation without systemic toxicity.
LRRC32 represents a differentiated Treg target compared to canonical markers like CD25 or CCR4, offering selective expression on activated regulatory T cells and platelets. The dominant therapeutic hypothesis centers on disrupting the immunosuppressive tumor microenvironment through inhibition of active TGF-β production, rather than global Treg depletion which risks autoimmunity. Additionally, combination strategies with anti-PD-1/PD-L1 agents and ADC conjugates for selective Treg ablation are advancing in preclinical and clinical stages.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | AbbVie, argenx, iTeos, Merck | Solid Tumors (NSCLC, CRC) | Receptor Blocking Assay / TGF-β Release Inhibition (Need high-purity LRRC32-TGFβ complex proteins) |
| ADC | Emerging Biotech, Early Discovery | Immunotherapy-resistant Cancers, Treg Depletion | Internalization Assay (Need full-length lentivirus-expressed target) |
| Bispecific (GARP x TGFb / GARP x PD-1) | Various Biotechs, Preclinical Programs | Immunotherapy Combos, Autoimmune Diseases | Complex Formation Assay / Cross-reactivity Panel (Need high-purity partners and ortholog comparison) |
Structural and Genetic Features
LRRC32 (GARP) contains two leucine-rich repeat domains, LRRNT and LRRCT, as annotated in UniProt Q14392. Key genetic variants include dbSNP:rs35033061, dbSNP:rs35130967, and a mutation in CPPRDD (UniProt VAR_051113, VAR_051114, VAR_085139). These variations may influence protein conformation and drug binding properties, and should be considered in assay design and patient stratification.